SARS-CoV-2

Dr Robert Hess: The flu season is just around the corner

Dr Robert Hess: The flu season is just around the corner: What you need to know about the influenza season in general and high-dose vaccines in particular. Social distancing, face coverings and strict hygiene controls not only reduced the spread of SARS-CoV-2 last year but also of influenza viruses. Flu activity is currently still at…

Read More

Dr Robert Hess: Could the Novavax vaccine candidate be a viable

Dr Robert Hess: Could the Novavax vaccine candidate be a viable alternative for skeptics wary of mRNA technology? We take a look at new data on the protein-based inactivated vaccine. Many people who are skeptical of mRNA technology have been waiting for a conventional vaccine against coronavirus to come along. “Classic” vaccines are traditionally based…

Read More

Dr Robert Hess: Evidence that Delta does not make children more ill

Dr Robert Hess: Evidence that Delta does not make children more ill than other variants of the coronavirus. The Delta variant of coronavirus does not appear to lead to a more severe course of disease in children than earlier forms of the virus, such as the Alpha or Beta variants. This finding emerged from a…

Read More

Dr Robert Hess: Booster jabs are contributing

Dr Robert Hess: Booster jabs are contributing to the individualization of the vaccination concept: Weighing up the potential side-effects of the Covid-19 vaccines and deciding the “price” we are willing to pay. As winter approaches in the northern hemisphere, booster vaccinations are being rolled out with the aim of giving maximum protection to the elderly,…

Read More

Dr Robert Hess: Corona drug molnupiravir

Dr Robert Hess: Corona drug molnupiravir significantly reduces number of severe cases of disease and raises hopes, says manufacturer. Merck Sharp and Dohme (MSD), the US pharmaceutical giant based in Kenilworth, New York, last week reported positive results from a Phase III trial of its new corona drug, molnupiravir. The manufacturer claim that it alleviates…

Read More

Dr Robert Hess: Current status and news of new concepts

Dr Robert Hess: Current status and news of new concepts such as antibody therapy and vaccination by inhalation against COVID-19 infection. Dr Robert Hess has a special interest in this topic, because for some of our premium members the conventional vaccination against Covid-19 is not an option or even can be counterproductive. We see these…

Read More

Dr Robert Hess: Update on new mutations

Dr Robert Hess: Update on new mutations and what you need to know about COVID-19 variants. As experts in the field of human and molecular genetics and thus also on the topic of mutations, we provide regular updates and forecasts of where the pandemic might be heading. Recently, new discoveries have come into the frame,…

Read More

Dr Robert Hess: Recent studies have established a strong link

Dr Robert Hess: Recent studies have established a strong link between the presence of autoantibodies against interferon-I and a severe progression of disease after infection with SARS-CoV-2. As we have explained in previous Keynotes, our body’s own interferon system plays an important role in the activation and modulation of the immune defenses. In this update,…

Read More

Dr Robert Hess: Any decision on whether to receive a booster jab

Dr Robert Hess: Any decision on whether to receive a booster jab (and which one to choose) or to wait for a next-generation vaccine should be based on the following criteria. 1 – Which is preferable – a booster jab or a next-generation vaccine? This depends on a number of factors, primarily which next-generation vaccine…

Read More

As Dr Robert Hess expected, the pandemic is becoming more complex

As Dr Robert Hess expected, the pandemic is becoming more complex and problematic in nature, which makes it all the more difficult to make any firm predictions for the autumn. In focus: Vaccine side-effects versus post-acute sequelae (“Long Covid”). The forecast of Dr Robert Hess in the spring of 2021 that the pandemic would take…

Read More